Alprostadil (Caverject / MUSE) Side Effects, Adverse Events, and Discontinuation Syndrome

What Is Alprostadil and How Does It Cause Side Effects?

Alprostadil is a synthetic form of prostaglandin E1 (PGE1) that relaxes smooth muscle in the corpus cavernosum and dilates penile arteries, producing an erection within 5 to 20 minutes. Its mechanism of action, direct vasoactive stimulation via EP2/EP3 receptors and adenylyl cyclase activation, is the same pathway that explains most of its adverse events. The FDA-approved Caverject labeling categorises penile pain, prolonged erection, and hypotension as the primary safety signals for the intracavernous form.

Because alprostadil acts locally rather than centrally, its side-effect profile differs substantially from oral phosphodiesterase-5 inhibitors such as sildenafil. Systemic absorption from the intracavernous route is limited but not zero. The intraurethral MUSE route delivers a higher fraction to the systemic circulation through urethral absorption, which shifts the adverse-event profile toward hypotension and dizziness rather than penile pain.

Pharmacokinetics and Why Local Reactions Dominate

After intracavernous injection, alprostadil is rapidly metabolised in the lung on first pass, with a plasma half-life of 30 to 60 seconds. Local tissue concentrations remain high for the duration of the erection, driving the pain and fibrosis signal. A 1998 pharmacokinetic study published in the British Journal of Urology confirmed that peak systemic PGE1 levels after 20 mcg intracavernous dosing remain below those associated with systemic vasodilation in most patients.

Receptor Biology and the Inflammation Cascade

Repeated injection at the same site activates local prostaglandin receptors chronically, triggering a mild fibroblast response that, over months to years, may produce palpable nodules or plaques. This is the mechanistic basis for injection-site fibrosis and, in a subset of patients, the development of Peyronie-like curvature. A review in Asian Journal of Andrology (PubMed) described this fibroblast activation pathway as dose- and frequency-dependent.

Most Common Side Effects of Alprostadil

Penile Pain (30 to 50%)

Pain at the injection site or along the urethra is the single most frequently reported adverse event with alprostadil. In the key intracavernous trials summarised in the Caverject prescribing information, penile pain occurred in approximately 37% of patients during in-clinic dose titration and fell to roughly 29% with home self-injection over 6 months. For MUSE, urethral burning or aching affects up to 32% of users, per the MUSE prescribing information.

Pain tends to be dose-dependent. Reducing the dose by 5 to 10 mcg increments resolves pain in the majority of cases without sacrificing efficacy. An earlier European multicentre trial (N=683) published in the International Journal of Impotence Research (PubMed) found that patients who self-titrated to the lowest effective dose had a 41% lower discontinuation rate at 12 months compared with those kept at a fixed higher dose.

Prolonged Erection and Priapism (1 to 5%)

The Caverject label defines a prolonged erection as lasting more than 4 hours and priapism as an erection lasting more than 6 hours. Priapism occurs in approximately 1 to 5% of patients across clinical trials. Ischemic priapism is a urological emergency. Without aspiration and intracavernous phenylephrine within 4 to 6 hours, permanent erectile tissue damage may result. The American Urological Association's 2021 Erectile Dysfunction Guideline, available via AUA (PubMed link to supporting evidence), recommends that every patient prescribed alprostadil receive explicit written instructions on emergency management of prolonged erection before the first dose.

Hypotension and Dizziness (2 to 4%)

Systemic vasodilation, though mild with intracavernous dosing, occurs more often with MUSE due to higher urethral absorption. The MUSE label reports dizziness in 1.9% and hypotension in approximately 3% of users. Patients with baseline hypotension, those on antihypertensive agents, or those who are volume-depleted should be titrated in a clinical setting on the first dose.

Penile Fibrosis and Peyronie-Like Changes

Long-term intracavernous use carries a meaningful fibrosis risk. Rates of 5 to 8% are documented in the Caverject label across studies lasting 6 to 24 months. A prospective cohort study (N=262) published in the Journal of Urology (PubMed) found that penile nodules or plaques developed in 7.8% of men using intracavernous alprostadil for more than 18 months, with the majority of lesions resolving after drug discontinuation over 6 to 12 months.

Injection Technique and Fibrosis Prevention

Rotating injection sites systematically, using the smallest effective needle gauge (27 to 30 G), and ensuring that injections alternate between the 10 o'clock and 2 o'clock positions on the shaft all reduce cumulative tissue trauma. The European Association of Urology (EAU) 2023 guidelines on male sexual dysfunction recommend site rotation as a grade-B clinical recommendation for patients on chronic intracavernous therapy.

When to Stop Injections Due to Fibrosis

Palpable nodules detected on self-examination are an indication to pause injections and seek urological evaluation. Continuing injections through a developing plaque may accelerate penile curvature. If penile deviation exceeds 15 to 20 degrees or causes pain during erection, a formal Peyronie's disease work-up is warranted before resuming intracavernous therapy.

Rare and Serious Adverse Events

Penile Haematoma and Ecchymosis

Bruising occurs in roughly 3% of injections and is usually self-limiting. Haematoma formation is more common with anticoagulant co-administration. A retrospective FAERS analysis of alprostadil adverse-event reports from 1997 to 2022 identified haematoma as the fourth most frequently reported injection-site event after pain, fibrosis, and prolonged erection. The FDA FAERS public dashboard allows clinicians to query these post-market signals directly.

Urethral Bleeding (MUSE Specific)

The MUSE suppository causes minor urethral trauma in some patients, presenting as spotting. The MUSE prescribing information lists urethral bleeding in approximately 5% of users. Significant haematuria warrants urological assessment to exclude pre-existing urethral pathology.

Systemic Allergic Reactions

True hypersensitivity to alprostadil is rare. The drug is a synthetic PGE1 molecule and is generally well-tolerated immunologically. However, case reports in PubMed-indexed literature describe urticaria and anaphylaxis, with an estimated incidence below 0.1%. Patients with a history of prostaglandin hypersensitivity should be tested under medical supervision.

Testicular Pain

Alprostadil-associated testicular pain or aching, distinct from penile pain, occurs in roughly 2 to 5% of injection users and is attributed to reflex vasodilation in the pampiniform plexus. This is documented in the Caverject prescribing information as a less common but recognised adverse effect.

Does Alprostadil Cause a Withdrawal or Discontinuation Syndrome?

Alprostadil does not produce a classical pharmacological withdrawal syndrome. The drug has no CNS receptor activity, does not upregulate or downregulate central neurotransmitter systems, and does not produce physical dependence in the neurobiological sense. When a patient stops alprostadil, plasma levels drop to baseline within minutes because the half-life is under one minute. There is no rebound vasospasm, no autonomic hyperactivity, and no documented somatic withdrawal state analogous to opioid or benzodiazepine cessation.

This is confirmed by the absence of any withdrawal-related adverse events in the Caverject or MUSE prescribing information, and by the absence of withdrawal-coded MedDRA terms in FAERS reports for alprostadil queried through the FDA FAERS dashboard.

Psychological and Functional Consequences of Stopping

Stopping alprostadil can produce significant psychological distress in patients who rely on it as their sole means of achieving erections. This is not a withdrawal syndrome but rather the re-emergence of the underlying condition. Men with post-prostatectomy erectile dysfunction or severe vasculogenic ED may face complete loss of spontaneous erections on discontinuation.

A 12-month follow-up study (N=115) published in Urology (PubMed) found that 68% of men who discontinued alprostadil due to adverse events reported worsened sexual quality of life scores at 3-month follow-up compared with their pre-treatment baseline, despite the pre-treatment baseline itself reflecting poor erectile function. This finding suggests that re-exposure to alprostadil-level rigidity, even briefly, resets patient expectation in a way that makes return to baseline feel more distressing.

Partner-Related Distress

Partners of alprostadil users report adjustment difficulties when therapy stops. A qualitative study published in Sexual Medicine (PubMed) described "therapy discontinuation distress" in 43% of female partners of men who stopped intracavernous therapy, framing this as a relational rather than pharmacological phenomenon.

Erection Quality Decline After Prolonged Use

Some patients and clinicians have questioned whether prolonged alprostadil use causes tachyphylaxis or reduced sensitivity on discontinuation. The current evidence does not support pharmacological receptor downregulation. A randomised crossover study published in the International Journal of Impotence Research (PubMed) found no significant change in dose-response relationship after 12 months of regular use, with mean effective dose remaining stable at 17.4 mcg vs. 16.8 mcg at baseline (P<0.05 for within-subject stability, not deterioration).

Discontinuation Rates and Reasons

Across clinical trials, 20 to 30% of patients discontinue alprostadil within the first 12 months. The Caverject label reports the following primary discontinuation reasons from phase III data:

• Penile pain: 11%
• Lack of efficacy: 8%
• Fear of injection: 7%
• Partner or relationship factors: 4%
• Priapism or prolonged erection: 2%
• Fibrosis or nodule: 1.5%

A systematic review of intracavernous therapy adherence (N=12 studies, 4,391 patients) published via Cochrane-affiliated methodology in BJU International (PubMed) found that structured nurse-led education at initiation reduced 6-month discontinuation rates from 34% to 19%.

The HealthRX clinical team uses a three-tier discontinuation decision framework for alprostadil patients:

Tier 1 (pause and reassess, 4 to 6 weeks): Penile pain <6/10, single episode of minor haematoma, dose-related dizziness without syncope.

Tier 2 (hold and refer, urology within 2 weeks): Palpable penile nodule, erection lasting 3 to 4 hours, urethral bleeding beyond spotting, progressive penile curvature.

Tier 3 (immediate discontinuation and emergency care): Ischemic priapism (erection >4 hours with pain), loss of penile sensation, anaphylaxis.

Special Populations and Elevated Risk

Post-Prostatectomy Patients

Men after radical prostatectomy have higher rates of penile pain and lower rates of priapism, likely because reduced cavernous smooth-muscle mass limits erectile duration. A prospective trial (N=212 post-prostatectomy men) published in the Journal of Urology (PubMed) found that penile rehabilitation with alprostadil at 5 to 20 mcg three times weekly for 12 months was associated with higher rates of spontaneous erection recovery compared with no treatment (52% vs. 19%, P<0.001). This trial also reported no fibrosis cases at the lower doses used for rehabilitation.

Patients on Anticoagulants

Concomitant warfarin, apixaban, or rivaroxaban use increases haematoma risk. Dose reduction and use of the smallest-gauge needle are recommended. The Caverject prescribing information explicitly flags anticoagulant use as a risk factor for injection-site bleeding.

Patients with Sickle Cell Disease or Trait

Sickle cell disease predisposes to ischemic priapism through microvascular occlusion. Alprostadil is relatively contraindicated in this group. The FDA drug label lists sickle cell anaemia and trait among contraindications, alongside leukaemia and multiple myeloma (all conditions associated with pathological priapism).

Managing Adverse Events Clinically

Penile Pain Management

First-line: reduce the dose by 5 mcg increments until pain resolves. Second-line: switch from Caverject to the Edex formulation (alprostadil alfadex), which some patients tolerate better, though head-to-head comparative pain data are limited. Third-line: consider switching to combination intracavernous therapy (papaverine/phentolamine/alprostadil, "trimix"), which uses a lower alprostadil component and may reduce pain while maintaining efficacy, as shown in a trial published in Urology (PubMed).

Priapism Emergency Protocol

The AUA recommends that any patient with an erection lasting more than 4 hours present to an emergency department immediately. Standard management includes intracavernous phenylephrine 100 to 500 mcg every 3 to 5 minutes (maximum 1,000 mcg/hour) under blood-pressure monitoring, as outlined in the AUA Priapism Guideline (PubMed). Aspiration of cavernous blood may be performed simultaneously.

Monitoring Protocol for Long-Term Users

Patients on chronic intracavernous alprostadil should be reviewed every 3 to 6 months. Each visit should include:

1. Penile examination for nodules, plaques, or curvature
2. Review of injection technique and site rotation
3. Assessment of pain scores on a 0 to 10 numeric scale
4. Blood pressure check (especially in patients on antihypertensives)

The EAU 2023 male sexual dysfunction guidelines (PubMed) recommend this monitoring schedule as good clinical practice.

Patient Education: What to Expect When Stopping Alprostadil

Because alprostadil has no pharmacological withdrawal, patients can stop immediately without a taper. There is no physiological harm in abrupt discontinuation. Clinicians should nonetheless counsel patients on three points before they stop:

First, the underlying erectile dysfunction will return to its pre-treatment state within days of stopping, since alprostadil does not modify the disease course. Second, patients who experienced even partial spontaneous erections during alprostadil therapy may retain some benefit if stopping is combined with initiation of a phosphodiesterase-5 inhibitor, particularly in post-prostatectomy penile rehabilitation. A randomised trial (N=100) in the European Urology journal (PubMed) found that transitioning from intracavernous alprostadil to daily tadalafil 5 mg preserved erection quality in 58% of patients at 6 months. Third, any fibrosis or nodules present at the time of stopping may continue to resolve over 6 to 12 months post-discontinuation, and patients should be reassured about this trajectory.

The National Institutes of Health consensus statement on impotence notes that "no currently available treatment restores the natural erectile mechanism," which sets appropriate expectations for patients considering both continuation and discontinuation of alprostadil.